Study of 3 Monoclonal Antibodies (REGN9933, REGN7508, and REGN9533) in Adult Participants With End-Stage Kidney Disease on Hemodialysis
← catalyst calendarNCT07759167 · readout in 218 d
Sponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →.
Phase
Phase 1
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
36estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-09-09 | estimated | When the study began enrolling |
| Primary completion | 2027-03-25 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-03-25 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- End-Stage Kidney Disease (ESKD)
Interventions
- Drug: REGN9933 — also filed as amrecibart
- Drug: REGN7508 — also filed as cenvacibart
- Drug: REGN9533
- Drug: Heparin
Primary outcomes
what the primary-completion date above is the date OFOccurrence of Treatment-Emergent Adverse Events (TEAEs)
measured Up to approximately 78 days
Severity of TEAEs
measured Up to approximately 78 days
Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed